Evidence map›Paper›PMID 41084080›Full record

ArticleRadiation oncology (London, England)2025

Analysis of metabolic liver function and MR-morphological cholestatic parameters after SBRT of liver metastases.

Constantin Dreher, Paulina Wojtal, Maren Johann, Alicia S Bicu, Lena Kaestner, Christel Weiss, Svetlana Hetjens, Anoshirwan A Tavakoli, Dominik Nörenberg, Oliver Blanck and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Constantin DreherDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany. constantin.dreher@medma.uni-heidelberg.de.ORCID https://orcid.org/0000-0001-5671-9389
Paulina WojtalDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Maren JohannDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Alicia S BicuDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Lena KaestnerDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Christel WeissDepartment of Medical Statistics and Biomathematics, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Svetlana HetjensDepartment of Medical Statistics and Biomathematics, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Anoshirwan A TavakoliDepartment of Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Dominik NörenbergDepartment of Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Oliver BlanckDepartment of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Hans OppitzDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Daniel BuergyDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Frank A GiordanoDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Judit Boda-HeggemannDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study examined the longitudinal changes in metabolic liver function and MR-morphological dilatation of intrahepatic bile ducts in patients with stereotactic body radiation therapy (SBRT) for liver metastases.

methodsThis retrospective study included 64 patients with SBRT of 84 liver metastases between February 2005 and January 2019. To evaluate hepatobiliary toxicity, the laboratory parameters albumin, alanine-transaminase (ALAT), aspartate-transaminase (ASAT), bilirubin and gamma-glutamyltransferase (GGT) and the qualitative dilatation of MR-morphological peritumoural, intrahepatic bile ducts were analyzed from pre- up to 12 months post-SBRT.

resultsThe liver metastases were irradiated with a median D50 to the GTV of BEDα/β=10 Gy = 134 Gy (range 51–219 Gy) resulting in a median mean dose Dmean-L-EQD2α/β=3 Gy = 11.8 Gy (range 0.4–65.6 Gy) to the total liver. The central hepatobiliary tract (cHBT) was exposed to a median Dmean-cHBT-BEDα/β=10 Gy = 8.3 Gy (range 0.1–81.6 Gy). Significant decreases in albumin and increases in GGT and bilirubin were observed up to 12 months post-SBRT. Dmean-L-EQD2α/β=3 Gy, Dmean-cHBT-BEDα/β=10 Gy and VBEDα/β=10Gy66Gy-cHBT and VBEDα/β=10Gy72Gy-cHBT were significant cofactors influencing the course of GGT, ASAT and bilirubin, but not for albumin and ALAT. MR-morphological, short- and long-term dilatation of peritumoural bile ducts were associated with significant higher VBEDα/β=10Gy66Gy-cHBT and VBEDα/β=10Gy72Gy-cHBT values and were significantly more frequent for SBRT of target volumes with < 3 cm distance to the cHBT.

conclusionSBRT of liver metastases was associated with minor alterations in metabolic liver function. High dose exposure and proximity of the liver metastases to the cHBT may lead to locoregional bile duct dilatation after SBRT. Further evaluation of metabolic and MR-morphological changes in liver function is recommended in personalised oncological treatment approaches for liver-directed therapies.

Indexed as

Bile Ducts, IntrahepaticCholestasisLiverLiver NeoplasmsMagnetic Resonance ImagingRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiotherapy DosageRetrospective StudiesLiverMetabolic liver functionMetastasesMRISBRTToxicity

Identifiers

PMID41084080
PMCPMC12516830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.